- al co hol ic ▁fat ty ▁li ver ▁disease . ▁ ▁Im mun other apy ▁ ▁Met ast atic ▁cancer ▁▁ ▁IL - 1 5 ▁has ▁been ▁shown ▁to ▁enh ance ▁the ▁anti - t um or ▁imm unity ▁of ▁CD 8 + ▁T ▁cells ▁in ▁pre - cl in ical ▁models . ▁A ▁phase ▁I ▁clin ical ▁trial ▁to ▁evaluate ▁the ▁safety , ▁dos ing , ▁and ▁anti - t um or ▁effic acy ▁of ▁IL - 1 5 ▁in ▁patients ▁with ▁met ast atic ▁mel an oma ▁and ▁ren al ▁cell ▁car cin oma ▁( k id ney ▁cancer ) ▁has ▁begun ▁to ▁en roll ▁patients ▁at ▁the ▁National ▁Instit utes ▁of ▁Health . ▁ ▁V acc ines ▁Ad j uv ants ▁ ▁Vector - based ▁ther apy ▁– ▁N only t ic ▁New castle ▁D ise ase ▁Vir us ▁( ND V ) ▁was ▁engine ered ▁to ▁express ▁recom bin ant ▁IL - 1 5 ▁protein ▁to ▁generate ▁an ▁N D V - mod ified ▁tum or ▁v acc ine . ▁Pre cl in ical ▁results ▁of ▁N D V - mod ified ▁tum or ▁v acc ine ▁showed ▁promise ▁by ▁cont rolling ▁mel an oma ▁tum or ▁growth ▁in ▁m ice . ▁A ▁recom bin ant ▁v acc in ia ▁virus ▁express ing ▁influen za ▁A ▁prote ins ▁and ▁IL - 1 5 ▁promoted ▁cross ▁protection ▁by ▁CD 4 + ▁T ▁cells . ▁A ▁Bru cel la ▁DNA ▁v acc ine ▁containing ▁IL - 1 5 ▁gene ▁en